<DOC>
	<DOCNO>NCT01001442</DOCNO>
	<brief_summary>This Phase I/IIa clinical study test safety anti-tumor activity BT062 define best dose treat patient relapsed refractory multiple myeloma multiple dose BT062 .</brief_summary>
	<brief_title>Safety Dose Determining Multi-dose Study BT062 Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Diagnosis active multiple myeloma accord International Myeloma Working Group diagnostic criterion Relapsed relapsed/refractory multiple myeloma Previous treatment immunomodulator proteosome inhibitor therapy Age ≥ 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status ( Zubrod ) ≤ 2 Ability understand willingness sign write informed consent document Ability adhere study visit schedule protocol procedures Life expectancy ≥ 12 week Normal organ marrow function Chemotherapy radiotherapy within 3 week ( 6 week nitrosoureas mitomycin C ) prior day 1 recover AEs due agent administer 3 week earlier Treatment another investigational agent study within 4 week day 1 Major surgery within 4 week day 1 ( include placement vascular access device tumor biopsy ) Antineoplastic therapy biological agent within 2 week day 1 Known HAHAs , HACAs , HAMAs response previous MAb therapy Previous treatment BT062 Malignancy within 3 year day 1 , trial indication multiple myeloma exclude treat nonmelanoma skin cancer , superficial bladder cancer carcinoma insitu cervix Severe diseases skin , colon , esophagus , eye within 1 year day 1 , judge Investigator Severe infection necessitate use antibiotic / antiviral screen period Clinically relevant active infection include active hepatitis B C human immunodeficiency virus ( HBV , HCV , HIV ) concurrent disease , judgment investigator , would make subject inappropriate enrollment study Acute relevant abnormality electrocardiogram ( ECG ) , judge Investigator . These abnormality define recent myocardial infarction , uncontrolled cardiac arrhythmia and/or pronounce disturbance electrical conduction system heart . Significant cardiac disease recent myocardial infarction ( ≤ 6 month prior day 1 ) , unstable angina , uncontrolled congestive heart failure , uncontrolled hypertension ( recurrent persistent increase systolic blood pressure ≥ 180 mm Hg diastolic blood pressure ≥ 110 mm Hg ) , uncontrolled cardiac arrhythmia , grade 3 ( Lown Criteria ) great cardiac toxicity prior chemotherapy History clinically significant drug alcohol abuse Unwillingness inability adhere requirement study Concomitant therapy corticosteroid ( except indicate low dose medical condition inhale steroid asthma , topical use , premedication administration certain medication ( include BT062 ) blood product treatment infusion reaction need ) Concomitant antineoplastic therapy include chemotherapy , radiotherapy , biological agent study Any condition , include laboratory abnormality , opinion Investigator place subject unacceptable risk include study Breastfeeding Unwillingness use effective contraceptive method study least 3 month administration study drug unless subject naturally infertile . ( Acceptable contraceptive method include oral injectable contraceptive , intrauterine device ( IUD ) , doublebarrier method , contraceptive patch , surgical sterilization , condom ) . Positive serum urine pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>